Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares dropped 0.8% during mid-day trading on Wednesday . The company traded as low as $1.22 and last traded at $1.28. Approximately 94,203 shares changed hands during trading, a decline of 94% from the average daily volume of 1,521,488 shares. The stock had previously closed at $1.29.
Qualigen Therapeutics Stock Performance
The company’s 50 day moving average price is $1.34 and its 200-day moving average price is $1.83. The stock has a market cap of $2.17 million, a P/E ratio of -0.17 and a beta of 0.24.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
See Also
- Five stocks we like better than Qualigen Therapeutics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
